AXIM Biotechnologies (OTC: AXIM), the company’s investment company of Medical Marijuana (OTC: MJNA), recently filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a patent on a chewing gum composition comprising cannabinoids and parthenolide or treatment of symptoms of migraines.
“Studies have estimated that migraines affect roughly 38 million people in the U.S. and the market currently lacks an effective natural treatment option for those people,” Medical Marijuana CEO Dr. Stuart Titus stated.
Cannabis Chewing Gum
AXIM plans to formulate a chewing gum that contains feverfew extract, cannabidiol (CBD) and/or cannabigerol (CBG) for treatment of symptoms that often accompany migraines, such as headache, pain, nausea, and light sensitivity. Feverfew has been proven to relieve and prevent symptoms of migraines.
The new formulation will be delivered through AXIM’s sustained-release chewing gum delivery technology to release active ingredients in a controlled manner into the oral cavity.
“AXIM is best known for its patent on chewing gum containing cannabinoids and our flagship CBD chewing gum product, CanChew+,” AXIM CEO John Huemoeller II stated. “With this patent application and AXIM’s current cannabis chewing gum products currently in development, we plan to bring a variety of treatment options to the market.”
The global migraine treatment market size is expected to reach $7.8 billion by 2025, according to Grand View Research.